Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells

• Hauptverfasser: Henrika Jodeleit (Verfasst von), Paula Winkelmann (Verfasst von), Janina Caesar (Verfasst von), Sebastian Sterz (Verfasst von), Lesca M. Holdt (Verfasst von), Florian Beigel (Verfasst von), Johannes Stallhofer (Verfasst von), Simone Breiteneicher (Verfasst von), Eckart Bartnik (Verfasst von), Thomas Leeuw (Verfasst von), Matthias Siebeck (Verfasst von), Roswitha Gropp (Verfasst von)
• Format: Buch
• Veröffentlicht: The Company of Biologists, 2021-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

This study's aim was to demonstrate that the combination of patient immune profiling and testing in a humanized mouse model of ulcerative colitis (UC) might lead to patient stratification for treatment with oxelumab. First, immunological profiles of UC patients and non-UC donors were analyzed f...